article thumbnail

How brands can tap into wellness – lessons from influencers

Bio Pharma Dive

Our latest research uncovers new insights on how brands can truly close the wellness gap and grow within their industry sectors.

Branding 279
article thumbnail

ASH23: Pharma branding, Editas’ high bar and clinical trial diversity

Bio Pharma Dive

Editas had the tall task Monday of convincing ASH attendees its gene therapy for sickle cell disease could improve on Casgevy and Lyfgenia.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmaceutical OTC brands are being outcompeted by private-label OTC brands in retail and e-commerce marketplaces

Bio Pharma Dive

Self-care and the resulting increased use of over-the-counter (OTC) medications is a growing global trend.

Branding 246
article thumbnail

Industry hails mandatory QR code on top 300 drug brands from Aug 1, 2023

AuroBlog - Aurous Healthcare Clinical Trials blog

Drug manufacturers have hailed the Drugs (Eighth Amendment) Rules, 2022 mandating barcode or quick response (QR) code on the label of top 300 brands of formulations from August 1, 2023, saying that QR codes will help identify misbranded or counterfeit medicines as well as recall the products if its quality gets compromised during manufacturing.

Branding 189
article thumbnail

Upscaling your brand strategy: New ways of planning

pharmaphorum

Learn how to upscale your brand strategy with new and innovative ways of planning. Discover effective brand planning strategies to take your brand to the next level.

Branding 114
article thumbnail

Diabetes advocacy group discourages use of compounded GLP-1 drugs

Bio Pharma Dive

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.

Pharmacy 306
article thumbnail

At least three oncology 2023 brand launches have blockbuster potential

Pharmaceutical Technology

An analysis of GlobalData’s analyst consensus sales and forecast database reveals that three out of 12 novel oncology brands that launched globally from November 2022 to December 2023 have the potential to reach blockbuster sales.

Branding 130